Connor Clark & Lunn Investment Management Ltd. Sells 81,830 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Connor Clark & Lunn Investment Management Ltd. trimmed its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 46.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,225 shares of the company's stock after selling 81,830 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.21% of Y-mAbs Therapeutics worth $1,239,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of YMAB. Price T Rowe Associates Inc. MD boosted its holdings in shares of Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company's stock worth $345,000 after buying an additional 1,657 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Y-mAbs Therapeutics by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company's stock worth $993,000 after acquiring an additional 2,760 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Y-mAbs Therapeutics by 66.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock valued at $113,000 after purchasing an additional 3,416 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in Y-mAbs Therapeutics by 4.2% during the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company's stock worth $1,084,000 after purchasing an additional 3,589 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Y-mAbs Therapeutics by 8.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company's stock valued at $1,461,000 after purchasing an additional 8,974 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Friday, November 15th. Canaccord Genuity Group restated a "buy" rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Morgan Stanley lowered their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating on the stock in a report on Tuesday, August 13th. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a "strong-buy" rating in a research note on Tuesday, August 13th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $21.38.

Insider Activity

In other news, insider Thomas Gad sold 65,000 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the transaction, the insider now directly owns 97,681 shares in the company, valued at $1,315,763.07. This trade represents a 39.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.50% of the stock is currently owned by company insiders.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $10.77 on Wednesday. Y-mAbs Therapeutics, Inc. has a twelve month low of $5.31 and a twelve month high of $20.90. The business's fifty day moving average is $13.64 and its 200 day moving average is $12.83.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. During the same period in the prior year, the firm earned ($0.18) earnings per share. Equities research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.64 EPS for the current year.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.